Dr. Lal PathLabs Declares Interim Dividend, Reports ₹6.60 Billion Q3 Revenue

Dr. Lal PathLabs Ltd, one of India’s leading diagnostic chains, has announced its financial results for the December quarter. The company reported consolidated revenue of ₹6.60 billion and net profit of ₹905 million, alongside the declaration of an interim dividend of ₹3.5 per equity share.

Key Highlights:

• Revenue from Operations: ₹6.60 billion in Q3 FY25.
• Net Profit: ₹905 million, reflecting stable profitability.
• Dividend Declared: Interim dividend of ₹3.5 per equity share.
• Sector Context: Diagnostic services continue to see steady demand across India.
• Strategic Outlook: The company remains focused on expanding its diagnostic network and enhancing service delivery.

The combination of strong financial performance and dividend declaration underscores Dr. Lal PathLabs’ commitment to balancing growth with shareholder returns. With a robust presence in diagnostic services, the company is well-positioned to capitalize on rising healthcare demand across the country.

Sources: Reuters, Company Filings